{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 0, "question": "How many clients does 2U, Inc. have as of December 31, 2023?", "prediction": "The financial statement does not specify the total number of clients. It only mentions that as of December 31, 2023, two university clients in the Degree Program Segment accounted for 10% or more of the company's consolidated accounts receivable.", "ground_truth": "2U, Inc. has more than 260 clients as of December 31, 2023."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, how many executive-sponsored business resource networks (BRNs) did the company have?", "prediction": "According to chunk 0, as of December 31, 2023, the company had 9 Business Resource Networks (BRNs) focused on different groups such as Black/African Americans, Women, LGBTQ+, Asian & Pacific Islanders, Latinx, Persons with disabilities, Jewish employees, Black African employees (in South Africa), and Parents and Caregivers.", "ground_truth": "The company had 9 executive-sponsored business resource networks."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 2, "question": "What was the net carrying value of the edX trade name as of December 31, 2023?", "prediction": "According to chunk 0, the net carrying value of the edX trade name as of December 31, 2023, was $76.7 million.", "ground_truth": "$76.7 million."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 3, "question": "What is the required minimum Recurring Revenues as per the Second Amended Credit Agreement?", "prediction": "According to the financial statement, the Second Amended Credit Agreement requires the Company to maintain $900 million minimum Recurring Revenues as of the last day of any period of four consecutive fiscal quarters.", "ground_truth": "$900 million."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 4, "question": "What is the term expiration year for the lease of 2U, Inc.'s headquarters in Lanham, Maryland?", "prediction": "According to chunk 2, the lease for 2U's headquarters in Lanham, Maryland expires in 2028.", "ground_truth": "2028."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 6, "question": "What was the translation adjustment loss for foreign currency for the year ended December 31, 2023?", "prediction": "According to chunk 0 and chunk 3, the foreign currency translation adjustment loss for the year ended December 31, 2023 was $5.7 million.", "ground_truth": "The foreign currency translation adjustment loss was $5.7 million."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 7, "question": "What kind of liabilities does the Company recognize related to uncertain tax positions?", "prediction": "According to the financial statement, the Company records a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. However, as of December 31, 2023 and 2022, the Company has not recognized any amounts for uncertain tax positions.", "ground_truth": "The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 8, "question": "What is the total future minimum payment that 2U, Inc. is obligated to make to university clients as of December 31, 2023?", "prediction": "According to the financial statement, the total future minimum payments to university clients as of December 31, 2023 is $17,569,000. This can be found in the table in chunk 1, which breaks down the payments from 2024 to 2028.", "ground_truth": "$17,569,000."}
{"type": "financial", "level": "location", "file": "2U, Inc..txt", "context_order": 9, "question": "How much stock-based compensation expense was recognized in 2022?", "prediction": "I apologize, but I cannot find the specific amount of stock-based compensation expense recognized in 2022 in the provided chunks. The text describes the accounting methods for stock-based compensation, but does not explicitly state the total expense amount for 2022.", "ground_truth": "$80.2 million."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 0, "question": "What is the name of the wholly-owned biotech company formed by 3D Systems in 2022?", "prediction": "Systemic Bio", "ground_truth": "Systemic Bio."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 1, "question": "Who is the company's Executive Vice President and Chief Technology Officer for Regenerative Medicine?", "prediction": "According to the document, Charles W. Hull is the Executive Vice President, Chief Technology Officer for Regenerative Medicine. He is a founder of the company and has served in various executive roles since 1986.", "ground_truth": "Charles W. Hull."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 2, "question": "How many shares of the company's common stock were surrendered for tax withholding obligations in December 2022?", "prediction": "According to chunk 0, 67,575 shares of common stock were surrendered for tax withholding obligations in December 2022.", "ground_truth": "67,575 shares of common stock were surrendered for tax withholding obligations in December 2022."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 3, "question": "What was the total revenue for the year ended December 31, 2022?", "prediction": "According to the financial statement, the total revenue for the year ended December 31, 2022 was $538,031,000.", "ground_truth": "$538.0 million."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 4, "question": "What percentage of 3D Systems' net sales in 2022 was attributable to entities with functional currencies other than the U.S. dollar?", "prediction": "According to the financial statement, approximately 39.4% of 3D Systems' net sales in 2022 were attributable to entities with functional currencies other than the U.S. dollar.", "ground_truth": "Approximately 39.4% of net sales."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 5, "question": "What was the net loss income attributable to 3D Systems Corporation for the year ended December 31, 2022?", "prediction": "According to the financial statement, the net loss income attributable to 3D Systems Corporation for the year ended December 31, 2022 was $122,711,000 (or $122.711 million).", "ground_truth": "$(122,711)"}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 6, "question": "What was the net income attributable to 3D Systems Corp. for the year ended December 31, 2021?", "prediction": "According to the financial statement, the net income attributable to 3D Systems Corporation for the year ended December 31, 2021 was $322,052,000.", "ground_truth": "$322,052."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 7, "question": "What was the fair value of cash acquired with the Volumetric acquisition?", "prediction": "According to the financial statement, the fair value of cash acquired with the Volumetric acquisition was $389.", "ground_truth": "$389."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 8, "question": "What was the total revenue for 3D Systems Corporation for the year ended December 31, 2022?", "prediction": "According to the financial statement, the total revenue for 3D Systems Corporation for the year ended December 31, 2022 was $538,031,000 (or $538.0 million).", "ground_truth": "$538,031,000."}
{"type": "financial", "level": "location", "file": "3D Systems Corp..txt", "context_order": 9, "question": "How many shares of restricted stock that vest under specified Company performance measures were included in the outstanding balance as of December 31, 2022?", "prediction": "According to the financial statement, 1,215 shares of restricted stock that vest under specified Company performance measures were included in the outstanding balance as of December 31, 2022.", "ground_truth": "1,215 shares of restricted stock."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 0, "question": "What date did Square, Inc. change its corporate name to Block, Inc.?", "prediction": "According to chunk 0, Square, Inc. changed its corporate name to Block, Inc. on December 1, 2021.", "ground_truth": "On December 1, 2021, Square, Inc. changed its corporate name to Block, Inc."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, how many full-time employees did the company have worldwide?", "prediction": "According to the human capital section, as of December 31, 2023, Block had 12,985 full-time employees worldwide, with 3,154 of those employees located outside the United States.", "ground_truth": "The company had 12,985 full-time employees worldwide."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 2, "question": "What portion of Bitcoin does the company hold in offline and air-gapped cold storage?", "prediction": "According to chunk 0, the vast majority of bitcoin held for themselves and their customers is held in offline and air-gapped cold storage. A small portion is kept in a networked hot wallet to facilitate transactions.", "ground_truth": "The vast majority of bitcoin we hold for ourselves and our customers is held in offline and air-gapped cold storage."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 3, "question": "As of December 31, 2023, what was the outstanding aggregate principal amount of 2025 Convertible Notes?", "prediction": "According to chunk 0 and chunk 1, the outstanding aggregate principal amount of 2025 Convertible Notes as of December 31, 2023 was $1.0 billion.", "ground_truth": "$1.0 billion."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 4, "question": "As of February 16, 2024, how many holders of record were there for Block, Inc.'s Class A common stock?", "prediction": "According to the financial statement, as of February 16, 2024, there were 637 holders of record of Block, Inc.'s Class A common stock.", "ground_truth": "As of February 16, 2024, there were 637 holders of record for Block, Inc.'s Class A common stock."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 5, "question": "What was the increase in net cash provided by investing activities for the year ended December 31, 2023?", "prediction": "According to the financial statement, cash provided by investing activities for the year ended December 31, 2023 was $683.2 million, primarily from net proceeds of marketable securities of $600.3 million and a net inflow from consumer receivables of $272.9 million.", "ground_truth": "Net cash provided by investing activities increased by $683.2 million."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 6, "question": "What was Block, Inc.'s total revenue for the year ended December 31, 2023?", "prediction": "According to the consolidated statements of operations in chunk 0, Block, Inc.'s total net revenue for the year ended December 31, 2023 was $21,915,623,000.", "ground_truth": "$21,915,623,000."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 7, "question": "What was the total net revenue for the year ended December 31, 2023?", "prediction": "According to the financial statement, the total net revenue for the year ended December 31, 2023 was $21,915,623.", "ground_truth": "$21,915,623,000."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 8, "question": "What was the credit provision for consumer receivables acquired from Afterpay from January 31, 2022, to December 31, 2022?", "prediction": "According to chunk 0, the provision for credit losses from January 31, 2022 to December 31, 2022 was $203,670 thousand.", "ground_truth": "$203,670,000."}
{"type": "financial", "level": "location", "file": "Block, Inc..txt", "context_order": 9, "question": "What was the total amount of shares repurchased by the Company during the year ended December 31, 2023?", "prediction": "According to the financial statement, the Company repurchased 2.5 million shares of its Class A common stock for an aggregate amount of $156.8 million during the year ended December 31, 2023.", "ground_truth": "2.5 million shares of Class A common stock."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 0, "question": "What was C.H. Robinson Worldwide, Inc.'s total consolidated revenue for the year ended December 31, 2023?", "prediction": "According to the Consolidated Statements of Operations, C.H. Robinson Worldwide, Inc.'s total consolidated revenue for the year ended December 31, 2023 was $17,596,443,000.", "ground_truth": "C.H. Robinson Worldwide, Inc.'s total consolidated revenue was $17.6 billion in 2023."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 1, "question": "What was the engagement score from the 2023 survey?", "prediction": "According to the first chunk, the 2023 engagement survey generated an engagement score of 77 percent.", "ground_truth": "77 percent."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 2, "question": "When did Michael P. Zechmeister plan to retire from his position as Chief Financial Officer?", "prediction": "According to the text, Michael P. Zechmeister will depart his position as Chief Financial Officer no later than May 31, 2024, at which time he plans to retire.", "ground_truth": "No later than May 31, 2024."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 3, "question": "Where is the corporate headquarters of C.H. Robinson Worldwide, Inc. located?", "prediction": "According to the document, C.H. Robinson Worldwide, Inc.'s corporate headquarters is located in Eden Prairie, Minnesota.", "ground_truth": "The corporate headquarters is in Eden Prairie, Minnesota."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 4, "question": "What was the diluted net income per share for the twelve months ended December 31, 2023?", "prediction": "According to the financial statement, the diluted net income per share for the twelve months ended December 31, 2023 was $2.72.", "ground_truth": "$2.72."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 5, "question": "What was the effect of exchange rates on cash and cash equivalents for the year ended December 31, 2023?", "prediction": "According to chunk 0 and chunk 2, the effect of exchange rates on cash and cash equivalents for the year ended December 31, 2023 was negative $3,284 thousand.", "ground_truth": "A decrease of $3,284,000."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 6, "question": "What was the opinion expressed by the auditing firm regarding C.H. Robinson Worldwide, Inc.'s internal control over financial reporting as of December 31, 2023?", "prediction": "According to the report, Deloitte & Touche LLP expressed an unqualified opinion that C.H. Robinson Worldwide, Inc. maintained effective internal control over financial reporting as of December 31, 2023, based on the criteria established in the Internal Control — Integrated Framework (2013) issued by COSO.", "ground_truth": "The auditing firm expressed that C.H. Robinson Worldwide, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 7, "question": "What was the carrying value of total debt as of December 31, 2023?", "prediction": "According to chunk 0, the carrying value of total debt as of December 31, 2023 was $1,580,487 thousand.", "ground_truth": "$1,580,487 thousand."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 8, "question": "What was the total value of shares repurchased by the company in 2023?", "prediction": "According to chunk 0, the total value of shares repurchased in 2023 was $62,778,000.", "ground_truth": "$62,778 thousand."}
{"type": "financial", "level": "location", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 9, "question": "What was the amount of total restructuring charges recognized for the 2023 South American Restructuring Program?", "prediction": "According to chunk 0, the total restructuring charges recognized for the 2023 South American Restructuring Program were $21.2 million, which included $2.237 million in severance and personnel expenses, $18.328 million in loss on disposal and exit activities, and $1.420 million in other miscellaneous expenses, offset by $795,000 in income tax benefits.", "ground_truth": "$21.2 million."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 0, "question": "What was the total revenue for Exact Sciences Corporation for the year ended December 31, 2023?", "prediction": "According to the financial statement, the total revenue for Exact Sciences Corporation for the year ended December 31, 2023 was $2,499,766,000.", "ground_truth": "$2.50 billion."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 1, "question": "As of December 31, 2023, how many issued patents does the company own in the U.S.?", "prediction": "According to chunk 0, as of December 31, 2023, the company had 208 issued patents in the U.S.", "ground_truth": "As of December 31, 2023, the company owns 208 issued patents in the U.S."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 2, "question": "What location houses both the headquarters and one of the test facilities?", "prediction": "Madison, Wisconsin houses both the company's headquarters and one of their test facilities.", "ground_truth": "Madison, Wisconsin houses both the headquarters and one of the test facilities."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 3, "question": "What was the settlement amount paid by the company in September 2023 due to a civil investigative demand related to Genomic Health's Medicare billing compliance?", "prediction": "According to the financial statement, the company paid $32.5 million in September 2023 to settle a civil investigation concerning Genomic Health's compliance with Medicare Date of Service billing regulations prior to its acquisition in 2019.", "ground_truth": "The settlement amount paid in September 2023 was $32.5 million."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 4, "question": "As of December 31, 2023, what is the total indebtedness of the company?", "prediction": "According to chunk 0 and chunk 3, the total indebtedness as of December 31, 2023 is $2.39 billion, which includes $2.34 billion in convertible senior notes and $50.0 million in borrowings under the Securitization Facility, plus $4.4 million in letters of credit.", "ground_truth": "The total indebtedness is $2.39 billion."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 5, "question": "What is the projected fiscal year range for the Thrive milestone payments related to FDA approval and CMS coverage?", "prediction": "According to the financial statement chunks, the projected fiscal year range for the Thrive milestone payments is from 2028 to 2030.", "ground_truth": "The projected fiscal year of payment range is from 2028 to 2030."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 6, "question": "What was the net loss for Exact Sciences Corporation for the year ended December 31, 2023?", "prediction": "According to the consolidated statements of comprehensive loss, Exact Sciences Corporation's net loss for the year ended December 31, 2023 was $204,149,000.", "ground_truth": "$204,149,000."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 7, "question": "What was the total revenue of EXACT Sciences Corporation for the year ended December 31, 2023?", "prediction": "According to the revenue table in chunk 0, the total revenue for Exact Sciences Corporation for the year ended December 31, 2023 was $2,499,766,000.", "ground_truth": "$2,499,766,000."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 8, "question": "When will the license agreement with Mayo expire?", "prediction": "According to the documents, the license agreement with Mayo will remain in effect until the last of the licensed patents expires in 2043 (or later, if certain patent applications are issued). If the company is still using Mayo's know-how or biological specimens after that date, the term can continue for up to five additional years.", "ground_truth": "The license agreement will remain in effect until the last of the licensed patents expires in 2039."}
{"type": "financial", "level": "location", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 9, "question": "What was the acquisition date fair value of the consideration transferred for the Ashion Acquisition?", "prediction": "According to the financial statement, the acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million, which consisted of $74,775,000 in cash, $16,224,000 in common stock issued, and $19,000,000 in contingent consideration.", "ground_truth": "The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 0, "question": "What was the total collaboration revenue recognized during the year ended December 31, 2023?", "prediction": "According to chunk 1, the total collaboration revenue recognized during the year ended December 31, 2023 was $38.0 million.", "ground_truth": "$38.0 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 1, "question": "What is the expiration date of U.S. Patent No. 7,335,799 covering bempedoic acid, including patent term adjustment?", "prediction": "According to the text, U.S. Patent No. 7,335,799 covering bempedoic acid is scheduled to expire in December 2025, which includes 711 days of patent term adjustment. The company has also requested a five-year patent term extension and believes the patent could be subject to a six-month pediatric exclusivity period.", "ground_truth": "December 2025."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 2, "question": "How many full-time employees did the company have as of December 31, 2023?", "prediction": "According to chunk 0, the company had 240 full-time employees as of December 31, 2023.", "ground_truth": "The company had 240 full-time employees as of December 31, 2023."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 3, "question": "Which regulatory authorities have granted approval for the company’s leading product candidates as an adjunct to diet and statin therapy for the treatment of primary hyperlipidemia?", "prediction": "According to the text, the company has obtained regulatory approval from the FDA, the European Commission (EC), and Swissmedic for their leading product candidates (NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI) as an adjunct to diet and statin therapy for the treatment of primary hyperlipidemia in adults with HeFH or ASCVD who require additional lowering of LDL-C.", "ground_truth": "The FDA, the EC, and Swissmedic."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 4, "question": "What is the annual aggregate coverage limit of the product liability insurance for clinical studies?", "prediction": "According to the first chunk, the annual aggregate coverage limit for product liability insurance for clinical studies is $10.0 million.", "ground_truth": "$10.0 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 5, "question": "What is the senior security interest granted to Oberland under the RIPA?", "prediction": "Based on the chunks, under the RIPA (Revenue Interest Purchase Agreement), the company granted Oberland a senior security interest in certain of its assets. Specifically, this means Oberland has a priority claim on these assets if the company defaults on its payment obligations or fails to meet certain covenant requirements. The exact specific assets are not detailed in these chunks, but the security interest gives Oberland the ability to take control of pledged assets if the company defaults.", "ground_truth": "A senior security interest in the company's assets."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 6, "question": "What was the net loss for Esperion Therapeutics, Inc. for the year ended December 31, 2023?", "prediction": "According to the Statement of Operations, the net loss for Esperion Therapeutics, Inc. for the year ended December 31, 2023 was $209,248,000.", "ground_truth": "$209.2 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 7, "question": "What were the net proceeds from the Registered Direct Offering for the year ended December 31, 2023?", "prediction": "According to chunk 0, the net proceeds from the Registered Direct Offering were approximately $51.3 million, after deducting placement agent fees and related offering expenses of $4.2 million.", "ground_truth": "Approximately $51.3 million."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 8, "question": "What was the net cash provided by investing activities for the year ended December 31, 2023?", "prediction": "According to chunk 2, the net cash provided by investing activities for the year ended December 31, 2023 was $42,500.", "ground_truth": "$42,500 thousand."}
{"type": "financial", "level": "location", "file": "Esperion Therapeutics Inc.txt", "context_order": 9, "question": "What is the effective annual imputed interest rate on the revenue interest liability as of December 31, 2023?", "prediction": "According to the financial statement, the effective annual imputed interest rate is 17.6% as of December 31, 2023.", "ground_truth": "17.6%."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 1, "question": "What percentage of the company's revenue for the year ended December 31, 2023, came from its insurance verticals?", "prediction": "Based on the revenue breakdown in chunk 0, the insurance verticals for the year ended December 31, 2023 were:\n- Property & casualty insurance: 42.3%\n- Health insurance: 48.0%\n- Life insurance: 6.3%\n\nTotal insurance verticals: 96.6% of revenue.", "ground_truth": "96.6% of the revenue."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 2, "question": "What was the aggregate principal amount outstanding under the 2021 Term Loan Facility as of December 31, 2023?", "prediction": "According to chunk 0, the aggregate principal amount outstanding under the 2021 Term Loan Facility as of December 31, 2023 was $171.0 million.", "ground_truth": "$171.0 million."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 3, "question": "Which cloud infrastructure provider does the company rely on for hosting its platform?", "prediction": "According to the chunks, the company relies on Amazon Web Services (AWS) for hosting its platform and cloud computing infrastructure.", "ground_truth": "The company relies on Amazon Web Services (AWS) for hosting its platform."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 4, "question": "What were the low and high closing sales prices of Class A common stock from the IPO through December 31, 2023?", "prediction": "According to the text, from the IPO in October 2020 at $19.00 per share through December 31, 2023, the low and high closing sales prices of Class A common stock ranged from $5.36 to $64.11 per share.", "ground_truth": "The low and high closing sales prices of Class A common stock ranged from $5.36 to $64.11 per share."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 5, "question": "What was the revenue generated by the company for the year ended December 31, 2023?", "prediction": "According to chunk 0, the revenue for the year ended December 31, 2023 was $388.1 million.", "ground_truth": "$388.1 million."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 6, "question": "What was the total Transaction Value for the year ended December 31, 2023?", "prediction": "According to the financial statement, the total Transaction Value for the year ended December 31, 2023 was $593,438,000 (or $593.4 million).", "ground_truth": "$593,438 thousand."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 7, "question": "What is the total amount of goodwill reported as of December 31, 2023?", "prediction": "According to chunk 0 and chunk 1, the total amount of goodwill reported as of December 31, 2023 is $47,739,000.", "ground_truth": "$47,739."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 8, "question": "What was the total revenue for MediaAlpha, Inc. for the year ended December 31, 2023?", "prediction": "According to the financial statement, the total revenue for MediaAlpha, Inc. for the year ended December 31, 2023 was $388,149,000.", "ground_truth": "$388,149,000."}
{"type": "financial", "level": "location", "file": "MediaAlpha, Inc..txt", "context_order": 9, "question": "What was the balance of operating lease liabilities classified as non-current as of December 31, 2023?", "prediction": "According to chunk 0, the operating lease liabilities classified as non-current as of December 31, 2023 was $1,650 thousand.", "ground_truth": "$1,650 thousand."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 0, "question": "What is the primary endpoint that the Phase 2b clinical trial of MM120 met for the treatment of generalized anxiety disorder?", "prediction": "According to the text, the primary endpoint was demonstrating statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety (HAM-A) rating scale compared to placebo at Week 4.", "ground_truth": "Statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety (HAM-A) rating scale compared to placebo at Week 4."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 1, "question": "When did the company enter into a collaboration with Dr. Matthias Liechti's lab at UHB?", "prediction": "According to the financial statement, the company entered into a multi-year, exclusive collaboration with Dr. Matthias Liechti's lab at University Hospital Basel (UHB) on April 1, 2020.", "ground_truth": "On April 1, 2020."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 2, "question": "What does the Pediatric Research Equity Act require certain NDAs to contain?", "prediction": "According to the text, the Pediatric Research Equity Act requires certain NDAs or NDA supplements to contain data that:\n1. Assess the safety and efficacy of the drug for claimed indications in all relevant pediatric subpopulations\n2. Support dosing and administration for each pediatric subpopulation where the product is safe and effective\n\nThe FDA may grant deferrals or waivers for this requirement.", "ground_truth": "Data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 3, "question": "What is the maximum timeframe for the evaluation of a marketing authorization application in the EU?", "prediction": "According to the text, the maximum timeframe for the evaluation of a marketing authorization application in the EU is 210 days, not including clock stops during which applicants respond to questions from the competent authority.", "ground_truth": "The maximum timeframe is 210 days, not including clock stops during which applicants respond to questions from the competent authority."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 4, "question": "As of December 31, 2023, how much cash and cash equivalents did the company have?", "prediction": "According to chunk 0, as of December 31, 2023, the company had $99.7 million in cash and cash equivalents.", "ground_truth": "$99.7 million."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 5, "question": "What was the amount available for issuance under the shelf registration statement at December 31, 2023?", "prediction": "According to chunk 0, at December 31, 2023, $99.8 million remained available for issuance under the shelf registration statement, of which $59.8 million is reserved for sales under the ATM (at-the-market equity offering program).", "ground_truth": "$99.8 million."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 6, "question": "What may cause material adverse changes in the final clinical trial data?", "prediction": "According to the retrieved chunks, material adverse changes in final clinical trial data may be caused by:\n\n1. Continued patient enrollment\n2. More patient data becoming available\n3. Audit and verification procedures\n4. Differences in data interpretation by regulatory agencies\n5. Unforeseen safety issues or adverse side effects\n6. Failure to demonstrate a drug's benefit\n\nThese factors can significantly alter preliminary or interim data, potentially harming the company's business prospects.", "ground_truth": "Material adverse changes in the final data compared to the interim data could significantly harm our business prospects."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 7, "question": "What impact does the failure to gain market access and acceptance of product candidates have on the company's revenue?", "prediction": "According to the financial statement, if the company's product candidates fail to gain market access and acceptance, it will have a material adverse impact on their ability to generate revenue and provide a satisfactory return on investments. Even if some product candidates achieve market access, the market may prove too small to generate significant revenue.", "ground_truth": "It will have a material adverse impact on the ability to generate revenue to provide a satisfactory, or any, return on investments."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 8, "question": "What happens if the pricing of our product candidates is set at unsatisfactory levels or if reimbursement is unavailable or limited?", "prediction": "According to the financial statement, if the pricing of product candidates is set at unsatisfactory levels or if reimbursement is unavailable or limited, the company would experience:\n\n1. Negative effects on revenue from sales\n2. Reduced potential profitability of product candidates in those countries\n3. Difficulty successfully commercializing the product candidates\n4. Inability to obtain a satisfactory financial return on product development investments\n\nThe documents emphasize that without adequate reimbursement and pricing, the company may not be able to realize an appropriate return on its investment in developing new therapies.", "ground_truth": "Our revenue from sales and the potential profitability of our product candidates in those countries would be negatively affected."}
{"type": "financial", "level": "location", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 9, "question": "As of December 31, 2023, how many full-time and part-time employees did the company have?", "prediction": "According to the chunks, as of December 31, 2023, the company had 57 full-time and part-time employees, consisting of 36 in research and development and 21 in general and administrative roles.", "ground_truth": "57 full-time and part-time employees."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 0, "question": "How many business segments does NVIDIA Corporation report its business results in?", "prediction": "Based on the financial statement chunks, NVIDIA Corporation reports its business results in two main segments: Compute & Networking and Graphics, plus an \"All Other\" category for unallocated expenses.", "ground_truth": "NVIDIA Corporation reports its business results in two segments."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 1, "question": "As of the end of fiscal year 2024, how many employees were engaged in research and development at NVIDIA?", "prediction": "According to the first chunk, 22,200 employees were engaged in research and development at NVIDIA as of the end of fiscal year 2024.", "ground_truth": "22,200 employees were engaged in research and development."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 2, "question": "What percentage of NVIDIA's revenue in fiscal year 2024 was generated from sales outside of the United States?", "prediction": "According to the financial statement, 56% of NVIDIA's total revenue in fiscal year 2024 was generated from sales outside of the United States.", "ground_truth": "56% of NVIDIA's revenue was generated from sales outside of the United States in fiscal year 2024."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 3, "question": "How many employees are in the region impacted by the geopolitical conflict in and around Israel?", "prediction": "According to the document, approximately 3,700 employees are in the region impacted by the geopolitical conflict in and around Israel.", "ground_truth": "There are approximately 3,700 employees in the region."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 4, "question": "What is the symbol under which NVIDIA's common stock is traded?", "prediction": "According to the document, NVIDIA's common stock is traded under the symbol NVDA on the Nasdaq Global Select Market.", "ground_truth": "NVIDIA's common stock is traded under the symbol NVDA."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 5, "question": "What was NVIDIA's total revenue for fiscal year 2024?", "prediction": "According to the financial statement, NVIDIA's total revenue for fiscal year 2024 was $60,922 million.", "ground_truth": "$60.9 billion."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 6, "question": "What was the amount of acquisition termination cost related to the Arm transaction recorded in fiscal year 2023?", "prediction": "According to the financial statement, NVIDIA recorded an acquisition termination cost of $1.4 billion in fiscal year 2023 related to the termination of the Arm Share Purchase Agreement, reflecting the write-off of the prepayment provided at signing.", "ground_truth": "$1.4 billion."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 7, "question": "What was the total shareholders' equity of NVIDIA Corporation as of January 28, 2024?", "prediction": "According to the Consolidated Balance Sheet in chunk 0, NVIDIA Corporation's total shareholders' equity as of January 28, 2024 was $42,978 million.", "ground_truth": "$42,978 million."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 8, "question": "What is the expected weighted average period over which the unearned stock-based compensation expense will be recognized for RSUs, PSUs, and market-based PSUs as of January 28, 2024?", "prediction": "According to the financial statement, the unearned stock-based compensation expense for RSUs, PSUs, and market-based PSUs is expected to be recognized over a weighted average period of 2.5 years as of January 28, 2024.", "ground_truth": "2.5 years."}
{"type": "financial", "level": "location", "file": "NVIDIA Corporation.txt", "context_order": 9, "question": "What was NVIDIA's total revenue for the year ended January 28, 2024?", "prediction": "I apologize, but I cannot find the total revenue amount for the year ended January 28, 2024 in these provided financial statement chunks. While the chunks show net income of $29,760 million and details about deferred revenue, the total revenue figure is not explicitly stated in these excerpts.", "ground_truth": "$60,922 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 0, "question": "What is the page number for the 'Signature' section in this financial statement?", "prediction": "Page 150, based on the page number shown in chunk 1.", "ground_truth": "150"}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 1, "question": "What is the expected expiration year of U.S. Patent No. 9,265,740 related to omadacycline?", "prediction": "According to the text, U.S. Patent No. 9,265,740 (a method of use patent for omadacycline) is expected to be extended until October 2030.", "ground_truth": "The method of use patent (U.S. 9,265,740) is expected to be extended until October 2030."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 2, "question": "What is the primary business segment for Paratek Pharmaceuticals, Inc. as defined by generally accepted accounting principles?", "prediction": "According to the financial statement, Paratek Pharmaceuticals, Inc. operates as a single segment, as defined by generally accepted accounting principles.", "ground_truth": "Paratek Pharmaceuticals, Inc. operates its business as a single segment."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 3, "question": "What is the withdrawal quantity of NUZYRA's second procurement accepted by BARDA in December 2022?", "prediction": "According to the chunks, the second procurement was for 2,500 treatment courses of NUZYRA, with a total value of $36.4 million, delivered to and accepted by BARDA in December 2022.", "ground_truth": "2,500 treatment courses of NUZYRA."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 4, "question": "What is the annual interest rate for the 4.75% Convertible Senior Subordinated Notes issued in April 2018?", "prediction": "4.75%, payable on November 1 and May 1 of each year, beginning on November 1, 2018.", "ground_truth": "The Notes bear cash interest at the annual rate of 4.75%."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 5, "question": "What was the net loss for the year ended December 31, 2022?", "prediction": "According to the financial statement, the net loss for the year ended December 31, 2022 was $63,566,000.", "ground_truth": "$63.6 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 6, "question": "What was the net loss for Paratek Pharmaceuticals, Inc. for the year ended December 31, 2022?", "prediction": "According to the Consolidated Statements of Operations and Comprehensive Loss, the net loss for Paratek Pharmaceuticals, Inc. for the year ended December 31, 2022 was $63,566,000 (or $63.566 million).", "ground_truth": "$63.6 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 7, "question": "What was Paratek Pharmaceuticals, Inc.'s accumulated deficit through December 31, 2022?", "prediction": "According to the Consolidated Balance Sheet, Paratek Pharmaceuticals, Inc.'s accumulated deficit through December 31, 2022 was $(930,449,000).", "ground_truth": "$930.4 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 8, "question": "What was the Company's total cash, cash equivalents and restricted cash as of December 31, 2022?", "prediction": "According to the financial statement, the Company's total cash, cash equivalents, and restricted cash as of December 31, 2022 was $34,373,000, which consists of $34,248,000 in cash and cash equivalents and $125,000 in short-term restricted cash.", "ground_truth": "$34.4 million."}
{"type": "financial", "level": "location", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 9, "question": "What was the total coupon interest expense recognized by the Company for the R-Bridge Loan Agreement in the year ended December 31, 2022?", "prediction": "According to chunk 0, the Company recognized $4.4 million in coupon interest expense for the R-Bridge Loan Agreement for the year ended December 31, 2022.", "ground_truth": "$4.4 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 0, "question": "Which two reportable segments does Tesla, Inc. operate?", "prediction": "According to the financial statement, Tesla, Inc. operates two reportable segments:\n\n1. Automotive\n2. Energy generation and storage", "ground_truth": "Automotive and energy generation and storage."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, what was Tesla's worldwide employee headcount?", "prediction": "According to the financial statement, Tesla's worldwide employee headcount as of December 31, 2023 was 140,473.", "ground_truth": "140,473."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 2, "question": "As of December 31, 2023, how much aggregate principal amount of indebtedness did Tesla and its subsidiaries have outstanding?", "prediction": "According to chunk 0 and chunk 1, Tesla and its subsidiaries had $4.68 billion in aggregate principal amount of indebtedness outstanding as of December 31, 2023.", "ground_truth": "$4.68 billion."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 3, "question": "What was the intra-day trading high and low of the company's common stock over the last 52 weeks?", "prediction": "According to the financial statement, the company's common stock experienced an intra-day trading high of $299.29 per share and a low of $152.37 per share over the last 52 weeks.", "ground_truth": "The intra-day trading high was $299.29 per share and the low was $152.37 per share."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 4, "question": "What was the automotive sales revenue for the year ended December 31, 2023?", "prediction": "According to the financial statement, the automotive sales revenue for the year ended December 31, 2023 was $78,509 million.", "ground_truth": "$78,509 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 5, "question": "What was Tesla, Inc.'s total revenue for the year ended December 31, 2023?", "prediction": "According to the financial statement, Tesla, Inc.'s total revenue for the year ended December 31, 2023 was $96,773 million.", "ground_truth": "$96,773 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 6, "question": "What was the total cash and cash equivalents and restricted cash as of December 31, 2023?", "prediction": "According to the financial statement, Tesla's total cash and cash equivalents and restricted cash as of December 31, 2023 was $17,189 million. This is broken down as $16,398 million in cash and cash equivalents, $543 million in restricted cash included in prepaid expenses and other current assets, and $248 million in restricted cash included in other non-current assets.", "ground_truth": "$17,189 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 7, "question": "What was the carrying value of digital assets, net, as of December 31, 2023?", "prediction": "According to chunk 1, the carrying value of digital assets, net as of December 31, 2023 was $184 million.", "ground_truth": "$184 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 8, "question": "What was Tesla's total revenue for the year ended December 31, 2023?", "prediction": "According to the Consolidated Statements of Operations, Tesla's total revenue for the year ended December 31, 2023 was $96,773 million.", "ground_truth": "$96,773 million."}
{"type": "financial", "level": "location", "file": "Tesla, Inc..txt", "context_order": 9, "question": "Which independent registered public accounting firm audited the effectiveness of internal control over financial reporting as of December 31, 2023?", "prediction": "According to the first chunk, PricewaterhouseCoopers LLP audited the effectiveness of Tesla's internal control over financial reporting as of December 31, 2023.", "ground_truth": "PricewaterhouseCoopers LLP."}
